Trailing-twelve-month (TTM) revenue is $120.65 Million with a year-over-year growth of +31.36%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $27,817,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $30,615,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-03-31 | $29,612,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $32,610,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $120,654,000 |
Current P/S: $255,882,310 market capitalization ÷ $120,654,000 TTM revenue = 2.12x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $32.61M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:15:32.949Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD |
|---|---|---|---|---|---|---|
| Dermal | $396,000 | $2M | N/A | N/A | N/A | N/A |
| Joint Pain Management Therapies | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $14M | $20M | $21M | $22M | $19M | $22M |
| UNITED STATES | $103M | $114M | $119M | $123M |
$120.65M
$120.65 Million
+31.36%
vs. $91.85M a year ago (TTM)
(2.48%)
5 Year compound annual growth rate
1 Year
+31.36%
3 Year
(9.37%)
5 Year
(2.48%)
10 Year
+1.55%
15 Year
+5.19%
20 Year
+7.16%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $112.82M | ($7.09M) | (5.91%) |
| 2024 | $119.91M | ($885,000) | (0.73%) |
| 2023 | $120.79M | +$6.96M | +6.12% |
| 2022 | $113.83M | ($33.97M) | (22.98%) |
| 2021 | $147.79M | +$17.34M | +13.29% |
| 2020 |
TTM Growth
+31.36%
3-Year CAGR
(9.37%)
5-Year CAGR
(2.48%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:15:32.949Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $83M |
| N/A |
| N/A |
| N/A |
| Joint Preservation and Restoration | N/A | N/A | $39M | $49M | $50M | $55M |
|---|
| Licensing, Milestone and Contract Revenue | N/A | N/A | N/A | $0 | N/A | N/A |
|---|
| Manufactured Product, Other | $6M | $6M | $8M | N/A | N/A | N/A |
|---|
| Non-Orthopedic | N/A | N/A | N/A | $10M | $8M | $10M |
|---|
| OA Pain Management | N/A | N/A | N/A | $90M | $98M | N/A |
|---|
| Orthobiologics | $94M | $101M | N/A | N/A | N/A | N/A |
|---|
| Product | $106M | $115M | $130M | $148M | N/A | N/A |
|---|
| Service | $24,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Surgical | $6M | $5M | N/A | N/A | N/A | N/A |
|---|
| $70M |
| $130.46M |
| +$15.85M |
| +13.83% |
| 2019 | $114.61M | +$9.05M | +8.58% |
| 2018 | $105.56M | ($7.87M) | (6.93%) |
| 2017 | $113.42M | +$10.04M | +9.71% |
| 2016 | $103.38M | +$10.38M | +11.16% |
